Discovery of a novel Raf kinase inhibitor.

We discuss the biology of Ras signal transduction and the epidemiology of ras mutations in association with disease as a background for the development of a Raf kinase inhibitor, BAY 43-9006. Knowledge of Ras effector pathways has permitted genetic validation of numerous targets involved in the Ras signaling cascade. A key Ras effector pathway involves the kinase cascade RAF/MEK/ERK (MEK: MAP/ERK kinase; ERK: extracellular signal related kinase). Indeed, we present studies of cell lines stably expressing mutant MEK constructs, which point to Raf kinase as a target for therapeutics with selective anti-tumor activity. Finally, a small molecule drug discovery program based on inhibition of Raf kinase activity is outlined and the initial pre-clinical development process of the Raf kinase inhibitor BAY 43-9006 is discussed.

[1]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[2]  D. Bar-Sagi.  A Ras by Any Other Name , 2001, Molecular and Cellular Biology.

[3]  S. Piantadosi,et al.  Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. , 2001, Cancer research.

[4]  M. J. Arboleda,et al.  Dominant negative mutants of mitogen-activated protein kinase pathway. , 2001, Methods in enzymology.

[5]  X. F. Zhang,et al.  Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. , 2001, Recent progress in hormone research.

[6]  J. Muscat,et al.  K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. , 1999, Carcinogenesis.

[7]  K. Shannon,et al.  Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. , 1999, American journal of medical genetics.

[8]  Channing J Der,et al.  Increasing complexity of Ras signaling , 1998, Oncogene.

[9]  K. Sugimachi,et al.  Second primary cancers after resection of lung adenocarcinoma with ras gene mutation. , 1998, Anticancer research.

[10]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[11]  C. Zheng,et al.  Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. , 1994, The EMBO journal.

[12]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[13]  S. Rodenhuis.  ras and human tumors. , 1992, Seminars in cancer biology.

[14]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[15]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.